Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Leukemia Research

Volumn 36, Issue 9, 2012, Pages 1093-1097

  Klimek, Virginia M ^a   Dolezal, Emily K ^a   Tees, Michael T ^a   Devlin, Sean M ^a   Stein, Karen ^b   Romero, Alejandro ^b   Nimer, Stephen D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

5 Azacytidine; Decitabine; Leukemia; Therapy related cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84864008372     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.025     Document Type: Article

References (22)

1. Mauritzson N., Albin M., Rylander L., Billstrom R., Ahlgren T., Mikoczy Z., et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002, 16:2366-2378.
2. Takeyama K., Seto M., Uike N., Hamajima N., Ino T., Mikuni C., et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000, 71:144-152.
3. Litzow M.R., Tarima S., Perez W.S., Bolwell B.J., Cairo M.S., Camitta B.M., et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010, 115:1850-1857.
4. Steensma D.P., Stone R.M. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematology/Oncol Clin North Am 2010, 24:389-406.
5. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
6. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
7. Steensma D.P., Baer M.R., Slack J.L., Buckstein R., Godley L.A., Garcia-Manero G., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27:3842-3848.
8. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
9. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
10. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Stefano A.P., Stein H., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, International Agency for Research on Cancer (IARC), Lyon.
11. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
12. Anderson J.R., Cain K.C., Gelber R.D. Analysis of survival by tumor response. J Clin Oncol 1983, 1:710-719.
13. Komrokji R.S., Alrawi E., Al Ali N., Perkins J., Field T., Epling-Burnette P.K., et al. Outcome of azacitidine treatment of patients with therapy related myelodysplastic syndrome. Leukemia Res 2011, 35(Supplement 1):S108-S109.
14. Voso M.T., Fianchi L., Criscuolo M., Levis A., Finelli C., Musto P., et al. Response to 5-azacytidine in therapy-related malignant neoplasms (t-MN). Leukemia Res 2011, 35(Supplement 1):S76.
15. Fadlallah J., Bally C., Quesnel B., Vey N., Dreyfus F., Turlure P., et al. AZA in the treatment of therapy related MDS and AML (tMDS/AML): a report on 60 patients by the groupe francophone des syndromes myelodysplasiques (GFM). ASH Annual Meeting Abstracts, vol. 116 2010, 2911.
16. Kantarjian H.M. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007, 109:1133-1137.
17. Cogle C.R., Imanirad I., Wiggins L.E., Hsu J., Brown R., Scornik J.C., et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 2010, 8:40-46.
18. De Padua Silva L., de Lima M., Kantarjian H., Faderl S., Kebriaei P., Giralt S., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009, 43:839-843.
19. Field T., Perkins J., Huang Y., Kharfan-Dabaja M.A., Alsina M., Ayala E., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009, 45:255-260.
20. Kim D.Y., Lee J.H., Park Y.H., Kim S.D., Choi Y., Lee S.B., et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 2011.
21. Lubbert M., Bertz H., Ruter B., Marks R., Claus R., Wasch R., et al. Non-intensive treatment with low-dose 5-aza-2[prime]-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009, 44:585-588.
22. Castro-Malaspina H., Jabubowski A.A., Papadopoulos E.B., Boulad F., Young J.W., Kernan N.A., et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008, 14:458-468.